Hledání článků
Filtry
Mathur M, Barratt J, Chacko B, et al. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. N Engl J Med 2024;390:20–31.
Schlaich MP, Bellet M, Weber MA, et al.; PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel‑group, phase 3 trial. Lancet 2022;400:1927–1937.
Tuttle KR, Hauske SJ, Canziani ME, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet 2024;403:379–390.
Chakravarty EF, Utset T, Kamen DL, et al. Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open‑label, randomised controlled trial. Lancet Rheumatol 2024;6:e168–e177.
Chen EWC, Chong J, Valluru MK, et al. Combining genotype with height‑adjusted kidney length predicts rapid progression of ADPKD. Nephrol Dial Transplant 2024;38:1–11.
Bhandari S, Mehta S, Khawaja A, et al. Evaluation of the stopping angiotensin converting enzyme inhibitor compared to angiotensin receptor blocker (STOP ACEi trial) in advanced and progressive chronic kidney disease. Kidney Int 2024;105:200–208.
de Rooij ENM, de Fijter JW, Le Cessie S, et al..; EQUAL Study Investigators. Serum Potassium and Risk of Death or Kidney Replacement Therapy in Older People With CKD Stages 4‑5: Eight‑Year Follow‑up.
Am J Kidney Dis 2023;82:257.e1–266.e1.
Delestre F, Charles P, Karras A, et al. Rituximab as maintenance therapy for ANCA‑associated vasculitides: pooled analysis and long‑term outcome of 277 patients included in the MAINRITSAN trials.
Ann Rheum Dis 2023 Nov 2:ard‑2023‑224623. doi: 10.1136/ard‑2023‑224623. Epub ahead of print.
N Engl J Med 2023 Nov 3. doi: 10.1056/NEJMoa2308550.